Clinical Trials
152 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
M.D. Anderson Cancer Center
VERDI
Dana-Farber Cancer Institute
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Oncorena AB
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Beth Israel Deaconess Medical Center
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
TTBF
University of California, San Francisco
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Brigham and Women's Hospital
Clinical Application of CAIX-Targeted PET Imaging in Tumors
Peking University Cancer Hospital & Institute
IRMK01
University Hospital, Bordeaux
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
Advanced Diffusion Imaging in Renal Cancer Patients
NYU Langone Health
SLM + Axitinib for Clear Cell RCC
University of Iowa
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Vanderbilt-Ingram Cancer Center
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
University of Southern California
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb
NORDIC-SUN
University of Aarhus
ARC-20
Arcus Biosciences, Inc.
LIAM Mc
University College Cork
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Institutes of Health Clinical Center (CC)
DUAL-NK RCC
Beijing Biotech
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
COSTAR-002
Peking University First Hospital
JIVAN
Aurigene Discovery Technologies Limited
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Aurigene Discovery Technologies Limited
TEJAS-2
Aurigene Discovery Technologies Limited
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
FIT-001
Kura Oncology, Inc.
Rein3DP-M
University Hospital, Bordeaux
NEOPAX
University of Colorado, Denver
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
National Institutes of Health Clinical Center (CC)
STEALTH-001
KaliVir Immunotherapeutics
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
Henry Ford Health System
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
ORCHID
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SPARCC
Dana-Farber Cancer Institute
MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers
Chang Gung Memorial Hospital